| Literature DB >> 20148647 |
Gerard P Slobogean1, Peter J O'Brien, Carmen A Brauer.
Abstract
BACKGROUND ANDEntities:
Mesh:
Substances:
Year: 2010 PMID: 20148647 PMCID: PMC2895348 DOI: 10.3109/17453671003587119
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Model variables
| Variable | Base case | Range | References |
|---|---|---|---|
| SSI: surgical site infection. | |||
| Incidence of SSI | |||
| Single-dose prophylaxis | 0.025 | 0.01–0.06 | |
| Superficial | 0.66 | ||
| Deep | 0.34 | 0.3–0.6 | |
| Multiple-dose prophylaxis | 0.02 | 0.01–0.06 | |
| Superficial | 0.57 | ||
| Deep | 0.43 | 0.3–0.6 | |
| Incidence of Abx-related | |||
| Risk per dose of 1st generation cephalosporin | 0.00028 | 0.0001–0.0013 | |
| Doses to treat superficial SSI | 40 | 28–56 | |
| Risk of | 0.011 | 0.008–0.016 | |
| Doses to treat deep SSI | 126 | 84–168 | |
| Risk of | 0.035 | 0.023–0.047 | |
| Costs (2007 USD) | |||
| ORIF ankle fracture | 2,481 | 2,000–10,000 | |
| Preparation and dose of cefazolin | 9 | 5–15 | |
| Single-dose prophylaxis | 9 | 5–15 | |
| Multiple-dose prophylaxis | 36 | 20–60 | |
| Superficial SSI | 2,319 | 500–5,000 | |
| Deep SSI | 5,255 | 3,000–15,000 | |
| | 4,689 | 2,270–14,717 | |
| Quality Adjusted Life Days (QALD) | |||
| Ankle fracture | 272 | 204–285 | |
| | 268 | 124–284 | |
| Superficial SSI | 272 | 204–285 | |
| Superficial SSI and | 268 | 124–284 | |
| Deep SSI | 267 | 123–283 | |
| Deep SSI and | 263 | 122–282 | |
Figure 1.Decision tree representing the single- or multiple-dose prophylaxis decision for the surgical treatment of a closed fracture. The probability of an event occurring is listed beneath each respective branch.
Health-related quality of life adjustments
| Event | Health state (utilities) | QALD |
|---|---|---|
| QALD: quality-adjusted life-days; | ||
| SSI: surgical site infection. | ||
| Ankle fracture | 0.34 for 30 days | 272 |
| 0.30 for 7 days | 268 | |
| Superficial SSI | 0.34 for 30 days | 272 |
| Superficial SSI and | 0.30 for 7 days | 268 |
| Deep SSI | 0.30 for 10 days | 267 |
| Deep SSI and | 0.25 for 7 days | 263 |
Base case analysis
| Prophylaxis | Cost ($) | QALD | ICER |
|---|---|---|---|
| QALD: quality-adjusted life-days; | |||
| ICER: incremental cost-effectiveness ratio. | |||
| Single | 2,576.49 | 272 | – |
| Multiple | 2,595.84 | 272 | Dominated |
Figure 2.Results of two-way sensitivity analysis. The incidence of surgical site infection (A) and the proportion of deep wound infection (B) for each prophylaxis strategy is varied throughout the range described in Table 1.
Figure 3.Results of Monte Carlo probabilistic sensitivity analysis. The incremental cost-effectiveness ratio for multiple-dose prophylaxis compared to the single-dose strategy is shown. A “willingness to pay” threshold of $137 per incremental QALD (dashed line) and the 95% confidence interval (ellipse) are also shown.